Drug intelligence / Profile preview

ConfometRx Target A metabolic program

Development stage: Preclinical
Lead developer: ConfometRx
Modality: Small Molecules

Overview

ConfometRx's Target A program is a small molecule drug candidate currently in IND-enabling studies for the treatment of metabolic diseases. Developed in collaboration with an undisclosed biopharmaceutical partner, the program leverages ConfometRx's proprietary platform for G protein-coupled receptor (GPCR) structure-based drug discovery. While the specific GPCR target remains undisclosed, the candidate is designed as a small molecule modulator to address metabolic dysfunction. The program represents one of the most advanced assets in the company's pipeline, having progressed through lead optimization into formal IND-enabling development.

Other names: Partner Program - Target A

Beyond the preview

Go deeper on ConfometRx Target A metabolic program.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ConfometRx Target A metabolic program.

Explore the full profile